RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADIAMYCIN AND CYTOXAN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 新辅助化疗可使原发性乳腺癌患者保乳和降低分期。新辅助化疗后较高的病理完全缓解率可预示较长的生存期。这项研究试图为HER-2阳性和HER-2阴性的II-III期乳腺癌患者确定一种毒性更低、潜在更有效的新辅助方案。这种新的辅助剂设置还允许对化疗前后肿瘤和正常组织的蛋白质谱、DNA和RNA谱进行探索性分析，以确定结果的预测和预后指标以及未来治疗的潜在目标。该项目将代表希望之城综合癌症中心临床和研究实体之间的多学科和转化性研究合作。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neo-adjuvant chemotherapy may allow breast preservation and down staging in patients with primary breast cancer. Higher pathological complete response rates following neo-adjuvant chemotherapy may predict for prolonged survival. This study will attempt to define a less toxic and potentially more effective neo-adjuvant regiment in patients with both HER-2 positive and HER-2 negative Stage II-III breast carcinoma. This neo-adjuvant setting also allows for exploratory analysis of protein profiles, DNA and RNA profiles of the tumor and normal tissue prior to and subsequent to chemotherapy in order to identify predictive and prognostics indicators of outcomes and potential targets for future therapy. This project will represent multidisciplinary and translational research collaborations amongst the clinical and research entities of the City of Hope Comprehensive Cancer Center.